ADC Therapeutics cites adverse market conditions in cancelling IPO
Switzerland
Adverse market conditions were the reason cited by ADC Therapeutics SA in cancelling its proposed US initial public offering on 2 October. The IPO was intended to raise up to $200 million through the issue of 8.2 million shares on the New York Stock Exchange.
But the offering was cancelled a little more than a week after the launch.